Showing 4091-4100 of 5771 results for "".
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr
- Nicox’s Licensee Bausch + Lomb Receives Approval for Vyzulta in the United Arab Emirateshttps://modernod.com/news/nicoxs-licensee-bausch-lomb-receives-approval-for-vyzulta-in-the-united-arab-emirates/2479326/Nicox announced that its exclusive global licensee Bausch + Lomb has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in the United Arab Emirates. Now approved in 12 countries
- Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, Byoovizhttps://modernod.com/news/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz/2479327/Samsung Bioepis Biogen announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Byooviz, a biosimilar candidate referencing Lucentis (ranibizumab), also known as SB11. Ranibizumab is an anti-VEGF (vasc
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Santen Receives FDA Approval for Verkazia for the Treatment of Vernal Keratoconjunctivitishttps://modernod.com/news/santen-receives-fda-approval-for-verkazia-for-the-treatment-of-vernal-keratoconjunctivitis/2479321/Santen announced that the FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, that causes seve
- Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenseshttps://modernod.com/news/bausch-lomb-expands-parameters-for-bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses/2479319/Bausch + Lomb announced the US launch of expanded parameters for Bausch + Lomb ULTRA Multifocal for Astigmatism contact lenses. The expansion, which includes the addition of -2.25D and -2.75D cylinder power parameters, will be part of the company’s standard offering of the lens and will ext
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directorshttps://modernod.com/news/william-j-link-phd-named-chairman-of-allegro-ophthalmics-board-of-directors/2479313/Allegro Ophthalmics announced that William J. Link, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance. “I am thrilled that Bill has agreed to serve as our board chairman and pleased to promote Stephanie as VP of
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro